breast CANCER

Study Title

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CRA (Phone 412-359-8162) 

Internal Reference: (RC-4701/NSABP B-43 Julian)

Study Title

A Multi-site Prospective, Non Randomized Study Utilizing the Contura® Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CRA (Phone 412-359-8162) 

Internal Reference: (RC-4560/CONTURA SenoRX S07-002 Julian)

Study Title

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CRA (Phone 412-359-8162) 

Internal Reference: (RC-3881/NSABP B-39 Julian)

Study Title

Vanderbilt University: Pre-Surgical Trial of Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CCRC (Phone 412-359-8162)

Study Title

Z1071:  A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CCRC (Phone 412-359-8162)

Study Title

A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Sandy Brown, RN, OCN (Phone 412-359-6408) 

Internal Reference: (RC-4852/NSABP FRP FB-6 Julian)

Study Title

A Phase 3 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer

Principal Investigator: Charles Geyer, M.D.

Please also contact study coordinator for more information:    

Gloria Flannery, RN (Phone 412-359-8379) 

Internal Reference: (RC-4790/Neratinib Geyer)

Study Title

Endocrine Therapy in Combination With Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer

Principal Investigator: John Lister, M.D.

Please also contact study coordinator for more information:    

Lisa Wilt, RN, BSN (Phone 412-578-4429)

Study Title

2010EAP, An Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer

Principal Investigator: Charles Geyer, M.D.

Please also contact study coordinator for more information:    

Sandy Brown, RN, OCN (Phone 412-359-6408)

Study Title

A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Susan Hebda, CRA (Phone 412-359-8162) 

Internal Reference: (RC-4845/NSABP B-46-I Julian)

Study Title

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Principal Investigator: Thomas Julian, M.D. and Helen Analo, M.D.

This trial is offered at both Allegheny General and Western Pennsylvania Hospital

Please also contact study coordinator for more information:

AGH

Gloria Flannery, RN (Phone 412-359-8379)

Internal Reference: (RC-4231/PACCT -1 Julian) ___________________________________________________

WP

Rich Wonder, RN, CCRC (Phone 412-204-8125)

Study Title

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab

Principal Investigator: Thomas Julian, M.D.

Please also contact study coordinator for more information:    

Gloria Flannery, RN (Phone 412-359-8379) 

Internal Reference: (RC-4549/NSABP B-44-I BETH Julian)

Study Title

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens

Principal Investigator: Thomas Julian, M.D. and Helen Analo, M.D.